A Retrospective Study of Mucopolysaccharidosis Type II in Brazil - Data from Brazilian Health System (DATASUS)

A Retrospective Study of Mucopolysaccharidosis Type II in Brazil - Data from Brazilian Health System (DATASUS)

Abstract Data on Mucopolysaccharidosis type II (MPS II) in Latin America are scarce. This retrospective database study, using data from the Informatics Department of the Brazilian Health System (DATASUS), aimed to estimate the prevalence of MPSII in Brazil from 2008 to 2020 and to describe demograph...

Full description

Bibliographic Details
Main Authors:	Fernanda Tenório, Carolina Fischinger Moura de Souza
Format:	Article
Language:	English
Published:	SciELO 2023-10-01
Series:	Journal of Inborn Errors of Metabolism and Screening
Subjects:	Mucopolysaccharidosis Type II SUS ICD-10 E76.1 Idursulfase Hunter Syndrome
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942023000100306&tlng=en

Similar Items

Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment
by: Karen S. Yee, et al.
Published: (2024-04-01)

Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II
by: Karen S. Yee, et al.
Published: (2024-03-01)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
by: Ryutaro Yamanishi, et al.
Published: (2019-06-01)

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
by: Melissa J. Hogan, et al.
Published: (2020-12-01)

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry
by: Marie Julianne C. Racoma, et al.
Published: (2021-07-01)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
by: Karen S. Yee, et al.
Published: (2023-11-01)

Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
by: Kazuyoshi Tomita, et al.
Published: (2021-11-01)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
by: Vincenza Gragnaniello, et al.
Published: (2022-06-01)

Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients
by: Rossella Parini, et al.
Published: (2015-06-01)

Mucopolysaccharidosis Type II in the Practice of the Physician
by: I.Y. Vatanskaya, et al.
Published: (2016-09-01)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
by: Joseph Muenzer, et al.
Published: (2017-10-01)

Avaliação prospectiva de 11 pacientes brasileiros com mucopolissacaridose II Prospective study of 11 Brazilian patients with mucopolysaccharidosis II
by: Louise L. C. Pinto, et al.
Published: (2006-08-01)

Management of Difficult Airway in a Patient with Mucopolysaccharidosis Type II
by: Damla Hanalioğlu, et al.
Published: (2019-08-01)

Audiological Profiling and Rehabilitation Outcomes in a Child with Mucopolysaccharidosis Type II
by: Kavassery Venkateswaran Nisha, et al.
Published: (2023-11-01)

Mucopolysaccharidosis Type-II with Pathognomonic Skin Appearance: A Case with Pebbling Sign
by: Ayşe Hitay İnan, et al.
Published: (2021-06-01)

A Case of Mucopolysaccharidosis II Caused by a Novel Variant with Skin Linear Hyperpigmented Streaks along Blaschko’s Lines
by: Viktoriia Sofronova, et al.
Published: (2023-03-01)

Clinical, Biochemical and Molecular Characteristics of Fifteen Patients with Mucopolysaccharidosis Type II in Western Turkey
by: Havva Yazıcı, et al.
Published: (2018-03-01)

Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II
by: Lock-Hock Ngu, et al.
Published: (2017-09-01)

Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series
by: Mei-Yan Chan, et al.
Published: (2023-09-01)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
by: Zbigniew Żuber, et al.
Published: (2023-06-01)

Enhanced osteoblastic differentiation of parietal bone in a novel murine model of mucopolysaccharidosis type II
by: Narutoshi Yamazaki, et al.
Published: (2023-12-01)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
by: Roberto Giugliani, et al.
Published: (2021-10-01)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
by: R. Giugliani, et al.
Published: (2017-09-01)

Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II
by: Heather Bilyeu, et al.
Published: (2020-10-01)

Gene Therapy for Mucopolysaccharidosis Type II—A Review of the Current Possibilities
by: Paweł Zapolnik, et al.
Published: (2021-05-01)

Mucopolysaccharidosis type II (Hunter syndrome) in a boy from the Republic of Serbia: A case report
by: Tubić-Vukajlović Jovana M., et al.
Published: (2023-01-01)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
by: Whiteman DAH, et al.
Published: (2017-08-01)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
by: Joseph Muenzer, et al.
Published: (2021-10-01)

Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
by: Hélène FE Gleitz, et al.
Published: (2018-07-01)

Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan
by: Yusuke Hattori, et al.
Published: (2023-12-01)

Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome)
by: H. Amartino, et al.
Published: (2014-01-01)

Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice
by: Miles C. Smith, et al.
Published: (2024-03-01)

Functional assessment of the genetic findings indicating mucopolysaccharidosis type II in the prenatal setting
by: Maria Fuller, et al.
Published: (2021-07-01)

Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan
by: Kimitoshi Nakamura, et al.
Published: (2024-03-01)

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment
by: Christian J. Hendriksz, et al.
Published: (2015-12-01)

Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II
by: Fabio Catalano, et al.
Published: (2023-12-01)

The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
by: L Chkioua, et al.
Published: (2020-05-01)

Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey
by: Heather Lau, et al.
Published: (2023-12-01)

Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course
by: Joo-Hyun Seo, et al.
Published: (2020-09-01)

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
by: Barbara K. Burton, et al.
Published: (2020-09-01)